selatogrel
Small moleculeexperimental
Clinical trial activity
10 trials · 3 clinical orgs · 0 marketing orgs
Phase 1
7
Phase 2
3
Phase 3
1
Phase 4
0
Earliest trial started Oct 1, 2011 (NCT01954615)
Timeline
Indications
Mechanism of action
- Purinergic receptor P2Y12ANTAGONIST
Purinergic receptor P2Y12 antagonist
- Purinergic receptor P2Y12INHIBITOR
P2RY12 inhibitor
Chemistry & pharmacology
Loading structure…
SMILES
CCCCOC(=O)N1CCN(C(=O)[C@H](CP(=O)(O)O)NC(=O)c2cc(N3CC[C@H](OC)C3)nc(-c3ccccc3)n2)CC1- Mol. weight
- 618.63 g/mol
- Lipinski Ro5
- 1 violation(s)
- Rule of 3
- No
- Chirality
- Single Stereoisomer
- Inorganic
- No
- Polymer
- No
Oral
No
Parenteral
No
Topical
No
Sources
- ChEMBLCHEMBL4297589 ↗
Also known as
- act-246475
- act-246475
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT07133191 | Phase 1 | Oct 7, 2025 | Viatris |
| NCT04957719 | Phase 3 | Aug 14, 2021 | Idorsia Pharmaceuticals Ltd. |
| NCT04557280 | Phase 1 | Nov 6, 2020 | Idorsia Pharmaceuticals Ltd. |
| NCT04406896 | Phase 1 | Jun 30, 2020 | Idorsia Pharmaceuticals Ltd. |
| NCT03814200 | Phase 1 | Jan 3, 2019 | Idorsia Pharmaceuticals Ltd. |
| NCT03593278 | Phase 1 | Jul 27, 2018 | Idorsia Pharmaceuticals Ltd. |
| NCT03487445 | Phase 2 | Jul 10, 2018 | Idorsia Pharmaceuticals Ltd. |
| NCT03384966 | Phase 2 | Feb 7, 2018 | Idorsia Pharmaceuticals Ltd. |
| NCT03430661 | Phase 1 | Jan 24, 2018 | Idorsia Pharmaceuticals Ltd. |
| NCT01954615 | Phase 1 | Oct 1, 2011 | Actelion |
Showing 10 of 10 trials
Page 1 / 1
Organizations
Research & Development (3)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Idorsia Pharmaceuticals Ltd. | For profit | 8 | 8 | 3 | 2018 |
| Actelion | For profit | 1 | 1 | 1 | 2011 |
| Viatris | For profit | 1 | 1 | 1 | 2025 |
3 organizations
Page 1 / 1